Innovative MulticOmponent Drug dEsign (IMODE) for enhancing regional strategic advantages in pharmaceutical and biomedical applications (Q4295784)
Jump to navigation
Jump to search
Project Q4295784 in France, United Kingdom, Belgium
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Innovative MulticOmponent Drug dEsign (IMODE) for enhancing regional strategic advantages in pharmaceutical and biomedical applications |
Project Q4295784 in France, United Kingdom, Belgium |
Statements
3,576,035.7 Euro
0 references
5,960,059.5 Euro
0 references
60.0 percent
0 references
1 July 2016
0 references
30 June 2021
0 references
Université de Lille|Université Lille1
0 references
51°2'9.60"N, 3°43'38.28"E
0 references
51°23'50.14"N, 0°32'18.10"E
0 references
52°37'45.70"N, 1°15'26.96"E
0 references
50°36'18.22"N, 3°2'24.90"E
0 references
51°21'21.64"N, 0°32'9.42"W
0 references
51°31'29.46"N, 0°7'26.18"W
0 references
50°36'41.08"N, 3°8'26.16"E
0 references
50°36'19.37"N, 3°1'42.78"E
0 references
51°23'30.80"N, 0°31'4.76"E
0 references
50°36'12.64"N, 3°2'14.75"E
0 references
50°37'57.11"N, 2°40'48.18"E
0 references
The overall objective is to enhance R&D on major societal challenges for improved healthcare by developing solutions for novel pharmaceutical products and medical devices through new multicomponent drug systems. Our strategy will involve major stakeholders in the field including Universities, small and large entreprises and final users (patients) as well as an economic development agency. Technology transfer and industrial competitiveness will be enhanced. Trainings through technological develop. will create highly skilled scientists reducing the shortage of qualified staff in the field. (English)
0 references